Table 1 Clinical characteristics in patients with type 2 MI.
Demographics | Type 2 MI (n = 14,883) | Type 1 MI (n = 182,879) | ||
|---|---|---|---|---|
Missing data | Missing data | |||
Age (years) | 78 (69–85) | – | 72 (63–80) | – |
Men | 7494 (50.4%) | – | 122,773 (67.1%) | – |
Risk factors | ||||
Current smoking | 1859 (12.5%) | 10 | 35,191 (19.2%) | 53 |
Hypertension | 9523 (64.0%) | 8 | 104,346 (57.1%) | 90 |
Diabetes | 4080 (27.4%) | 11 | 40,282 (22.0%) | 131 |
Hyperlipidemia | 6631 (44.6%) | 18 | 62,622 (34.3%) | 257 |
Body mass index (kg/m2) | 25.8 (23.1–29.2) | 1393 | 26.6 (24.1–29.7) | 10,191 |
eGFR (mL/min/1.73m2) | 61.5 (41.2–82.0) | 630 | 76.3 (56.8–90.1) | 5489 |
Comorbidities | ||||
Previous MI | 5563 (37.4%) | 13 | 51,391 (28.1%) | 118 |
Previous PCI/CABG | 4082 (27.5%) | 13 | 44,286 (24.2%) | 121 |
Heart failure | 2754 (18.5%) | 13 | 18,105 (9.9%) | 131 |
Atrial fibrillation (adm.) | 3777 (25.4%) | 40 | 16,626 (9.1%) | 538 |
Previous stroke | 1904 (12.8%) | 14 | 14,736 (8.1%) | 144 |
Peripheral artery disease | 1752 (11.8%) | – | 11,654 (6.4%) | – |
COPD | 2538 (17.1%) | – | 13,942 (7.6%) | – |
Previous/present cancer | 1247 (8.4%) | – | 8229 (4.5%) | – |
Diagnostic procedures | ||||
Echocardiography | 9735 (65.4%) | – | 149,386 (81.9%) | – |
Coronary assessment | 5301 (39.6%) | – | 89,681 (79.5%) | – |
Discharge medications* | ||||
Betablockers | 10,814 (78.3%) | – | 144,893 (85.9%) | – |
RAAS–inhibitors | 5990 (75.6%) | – | 95,643 (87.3%) | – |
Statins | 9296 (66.1%) | – | 158,811 (91.1%) | – |
Discharge medications in patients with CAD* | ||||
Betablockers | 6183 (85.5%) | – | not assessed | – |
RAAS–inhibitors | 3539 (78.0%) | – | not assessed | – |
Statins | 5632 (76.5%) | – | not assessed | – |
